ReviewStem cells translational medicine2021

Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.

Balendu Shekhar Jha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.